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ABSTRACT 
ANTIPSYCHOTIC DRUG USE AND POSTMENOPAUSAL BREAST CANCER 
RISK IN THE WOMEN’S HEALTH INITIATIVE (WHI): A PROSPECTIVE 
COHORT STUDY 
MAY 2019 
ANNA GEORGE, B.S., TEXAS A&M UNIVERSITY 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Dr. Katherine Reeves 
Breast cancer is the most prevalent form of cancer and the second leading cause 
of mortality, affecting 1 in 9 women in the United States. Recent studies have shown that 
antipsychotic drug use is associated with increased prolactin levels, which, in turn, is 
associated with increased risk of breast cancer. However, studies of the association 
between antipsychotic drug use and the risk of breast cancer are sparse and have largely 
been conducted in homogenous populations. Therefore, we evaluated this relationship in 
postmenopausal women (N = 119 524) in a diverse population of the Women’s Health 
Initiative (WHI) cohort. Antipsychotic drug use was self-reported and in situ and invasive 
breast cancer cases were confirmed by medical records for the WHI clinical trial (CT) 
and the WHI observational study (OS), from 1993 through 2018. We used Cox 
proportional hazards regression to model breast cancer risk against antipsychotic drug use 
while adjusting for dietary and lifestyle factors. Overall, antipsychotic users made up 
0.41% of this population. There was no overall association between antipsychotic drug 
use and postmenopausal breast cancer risk (HR = 1.01, 95% CI = 0.73 – 1.40). Among 
typical antipsychotic drug users, there was a suggested two-fold increased risk in 
 iv 
developing in situ breast cancer (HR = 2.02, 95% CI = 0.84, 4.86). Thus, 
antipsychotic drug use does not appear to increase breast cancer risk overall, but the 
potential association between antipsychotics and in situ breast cancer merits further 
study. 
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CHAPTER I 
BACKGROUND AND SIGNIFICANCE 
 
A. Introduction 
In recent years, both cancer incidence and mortality are increasing rapidly on a global 
scale.1 Among women in the United States, breast cancer is the most prevalent form of cancer 
and the second leading cause of cancer mortality, affecting 1 in 9 women.2,3 According to the 
American Cancer Society, approximately 266, 120 new cases of invasive breast cancer will be 
diagnosed and 40, 920 deaths will occur in women in 2018.4 According to the 2018 statistics 
from the World Health Organization, the age adjusted incidence rates for breast cancer among 
females in North America is 84.8 per 100, 000 women.5  
There are both modifiable and non-modifiable risk factors associated with breast cancer. 
Women who have inherited mutations to certain genes, such as BRCA1 and BRCA2, are at 
higher risk of developing postmenopausal breast cancer.6 In addition, women with early onset of 
menses or menopause after the age of 55 are at an increased risk of postmenopausal breast 
cancer. Late age at menopause significantly increases postmenopausal breast cancer risk due to 
longer estrogen exposure among those entering menopause at older ages.7 Having a family 
history of breast cancer also increases the risk of breast cancer, especially when it involves a 
first-degree relative.6 Some modifiable factors include obesity, being physically active as well as 
moderately consuming alcohol.6 Certain forms of hormone replacement therapy (HRT) as well 
as current use of oral contraceptives have been found to increase breast cancer risk.6  
Another potential modifiable factor is medication use, particularly antipsychotic drug use. 
In the United States, psychiatric medication sales are among the five top drug sales in the 
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country.8 Based on data extracted from the IQVia Total Patient Tracker Database, approximately 
6, 430, 052 adults aged 45 and above use antipsychotics.9 While these statistics do not 
differentiate between men and women, data has shown that nearly twice as many women 
compared to men reported taking psychiatric drugs.10  
 
B. Physiology of Exposure-Outcome Relationship 
There is one potential mechanism that describes the physiological relationship between 
antipsychotic drug use and risk of breast cancer. Antipsychotics, also known as neuroleptics, 
serve as dopamine antagonizers that block post-synaptic D2 receptors located in the pituitary 
gland.8 This blockade occurs in the mesolimbic and mesocortical areas of the brain, and is 
integral to antipsychotic efficacy.11 Prolactin (PRL) is a 199-amino acid polypeptide hormone 
secreted in the lactotroph cells within the anterior pituitary.11 PRL secretion is controlled by both 
peptide and steroid hormones as well as neurotransmitters, which act as inhibitory and 
stimulatory factors. With regards to humans and animals, dopamine is the main prolactin-
inhibiting factor. Once dopamine binds to dopamine D2 receptors on the membrane of the 
lactotroph cells, this stimulation causes effects on PRL gene transcription. Elevated PRL levels 
are a common adverse effect of antipsychotic drug use, especially with typical antipsychotics 
(first-generation drugs).12,13  In contrast, atypical antipsychotics (second-generation drugs) cause 
smaller PRL elevations, with risperidone being an exception, as it has been shown to cause a 
significant increase in PRL levels compared to the other atypical antipsychotics.12,14 
PRL physiologically causes breast enlargement in pregnancy and is responsible for milk 
production during lactation.11 High levels of PRL, otherwise known as hyperprolectinemia, can 
increase the risk of breast cancer.15 For example, in the 1990s, there was evidence that related 
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PRL and breast cancer through a study that showed how activation of the prolactin receptor 
(PRLR) induced mammary carcinomas in transgenic mice.16 In addition, another study showed 
that human breast cancer cells had a higher expression of PRLR levels as compared to normal 
breast tissue.17 Cells in breast carcinomas are highly sensitive to PRL stimulation through these 
receptors.18 Apart from having a paracrine effect, it was also suggested that PRL has an autocrine 
effect on breast cancers and stimulates the growth of malignant neighboring cells in the breast in 
the presence of a carcinoma.19 To further support those claims, a study conducted by Tworoger 
et al. involving the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII) cohort 
showed an increased risk for higher proximate prolactin levels (RR, >15.7 vs. 8.1 ng/mL [i.e. top 
vs. bottom quartiles] =1.20, 95% CI = 1.03 – 1.40, p-trend = 0.005). More interestingly, the 
positive association was stronger for ER+ disease (RR = 1.28, p-trend = 0.003) and 
postmenopausal women (RR = 1.37, p-trend = 0.0002)..20 Therefore, we propose to investigate 
the relationship between antipsychotic drug use and breast cancer risk among postmenopausal 
women using data from all eligible participants enrolled in the Women’s Health Initiative. 
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CHAPTER II 
STUDY DESIGN AND METHODS 
 
A. Study Population 
The study population was drawn from the WHI cohort. Our analyses included all 
postmenopausal women from both the clinical trial (CT) and observational study (OS) aged 50-
79 years old enrolled in 1997 and followed-up through March 21, 2018 (N = 161 808). 
Participants had to be able as well as willing to provide written informed consent and planned to 
reside within the same area for at least 3 years after enrollment.  
 Participants were excluded from both the CT and OS if they had medical conditions 
predictive of a survival time of less than 3 years as well as having conditions or characteristics 
inconsistent with study participation and adherence.21 These conditions included alcoholism, 
drug dependency, mental illness and dementia. Participants were also excluded if they were 
active in another randomized controlled clinical trial. In addition, any competing risks were a 
cause for exclusion, which included invasive cancer in the past 10 years, breast cancer at any 
time or suspected breast cancer at baseline screening, acute myocardial infarction, stroke, 
transient ischemic attack in the past six months, chronic active hepatitis and cirrhosis.21 Each CT 
component had its own specific exclusionary criteria, which is described in further detailed 
elsewhere.21 For the purposes of our study, we excluded women with a personal history of breast 
cancer (N = 10 421). 
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B. Outcome Assessment  
 Postmenopausal breast cancer was assessed through annual self-report in which 
participants were required to report physician diagnosis of new cancer, a malignant tumor or 
growth of any type. From this self-reported information, medical records were retrieved and all 
cases were adjudicated, whereby cases were confirmed by a team of internal physicians within 
the WHI. Additionally, information on disease stage, subtype and tumor characteristics were 
collected. Incident cases of breast cancer was measured by assessing the questionnaires filled out 
in the WHI. We then categorized participants into “Yes” for those diagnosed with breast cancer 
and “No” for participants free of the disease. 
 
C. Exposure Assessment 
An inventory of current medications was collected at Screening Visit 1 (SV1) to ensure 
participants were not taking any protocol-excluded medications or supplements as well as to 
collect baseline information. Each participant was required to bring all their medications during 
the clinical visit, which was to be placed in a WHI bag. This includes all prescription 
medications, over-the-counter (OTC) medications, vitamins, minerals and bulk fiber 
supplements. If the participant forgot to bring any of her medications, this information was then 
collected during SV2. Each medication was then entered into a database after information on 
name as well as dosage of these medications were obtained by a research nurse. 
 For our study, we examined risk according to typical and atypical antipsychotic use based 
on medical data within the WHI with a TCCODE subcode of 590000, which was then further 
categorized based on similarities in molecular structure and chemical composition. Typical 
antipsychotics included phenothiazines (Fluphenazine, Chlorpromazine; TCCODE 592000), 
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butyrophenones (Haloperidol; TCCODE 591000), thioxanthenes (Thiothixene, Flupenthixol; 
TCCODE 593000) and indole derivatives (Molindone; TCCODE 591600). On the other hand, 
atypical antipsychotics comprised benzisoxales (Risperidone; TCCODE 590700), dibenzapines 
(Clozapine, Olanzipine,; TCCODE 591500) quinolinone derivatives (Aripiprazole; TCCODE 
592500) and others. We then categorized participants into “Non-Users and “Users”, who were 
then categorized further into “Atypical antipsychotic” and “Typical antipsychotic”. 
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CHAPTER III 
DATA ANALYSIS 
 
 Baseline descriptive statistics were calculated for all initial covariates based on 
antipsychotic drug use and postmenopausal breast cancer diagnosis (Table 1 and Table 2). 
Potential covariates were identified based on a priori knowledge of potential confounders of this 
relationship. T-tests and chi-square tests were performed for all continuous and categorical 
variables, respectively. 
 Cox proportional hazards models were used to estimate the hazard ratio (HR) and 
confidence intervals (CI) for the association between antipsychotic drug use and risk of 
postmenopausal breast cancer. As this was a survival analysis, censoring events were taken into 
consideration to define when follow-up ended for each participant. For participants diagnosed 
with breast cancer, follow-up ended when first diagnosed with breast cancer. Censoring for 
invasive breast cancer occurred at the first diagnosis of invasive breast cancer and censoring for 
in situ breast cancer occurred at the first diagnosis of in situ breast cancer. There was a small 
number of participants who were first diagnosed with in situ breast cancer and then proceeded to 
develop invasive breast cancer. Under that circumstance, the latter diagnosis was used as the 
time to event for the total breast cancer analysis. On the other hand, censoring for non-cases 
occurred at the end of follow-up or in the event of death. An unadjusted HR was calculated as 
well as age- and multivariable adjusted HR, controlling for potential confounders. Univariable 
Cox models were used to determine which covariates were to be included in the initial 
multivariable model, whereby covariates with p < 0.25 were included. Backward elimination and 
weighted likelihood-ratio tests were used to assess statistical significance of each covariate to 
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ensure a parsimonious yet reasonable model. This process was repeated until all covariates had a 
>10% change in the beta values obtained. Covariates included in the final multivariable model 
were alcohol intake, age, BMI, first-degree family history of breast cancer, education, ethnic 
group, HRT use, HT arm enrollment, 
parity, smoking status, Healthy Eating Index (HEI) score,22 total energy expended from 
recreational physical activity and age at menopause. All analyses were performed using SAS, 
version 9.4 (SAS Institute Inc., Cary, North Carolina) and all tests of statistical significance were 
based on two-sided p-values set at 0.05. 
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CHAPTER IV 
RESULTS 
 
Within the WHI cohort, there were 161 808 eligible participants who were enrolled. Our 
study had a total of 119 524 participants after applying an exclusion criterion of having ever been 
diagnosed with breast cancer. Among those eligible in this analysis, 119 166 (99.6%) were not 
antipsychotic drug users whereas 478 (0.40%) reported being users (Table 1). The mean age 
(SD) at enrollment was 63.1 (7.2) for non-users and 62.2 (7.2) for users. Compared to non-users, 
users were more likely to be overweight, had less than $35 000 in family income and were 
current drinkers (P<0.05). Overall, participants who were non-users and users of antipsychotic 
drugs had a statistically significant difference across all levels of each covariate (P < 0.05), 
except for ethnic group, education, HRT use and female relative having had breast cancer. 
In regards to postmenopausal breast cancer diagnosis, 9559 (8.0%) participants were 
diagnosed with the disease (Table 2). The majority of cases were aged 60 to 69, overweight, 
white, never smokers, current drinkers and current HRT users. Breast cancer cases were slightly 
younger at enrollment (mean, 62.6; SD, 6.9), on average, compared to non-cases (mean, 63.1; 
SD, 7.2). 
 Table 3 describes the distribution of cancer subtypes by antipsychotic drug use in this 
particular cohort. Among antipsychotic users, there was no variation in disease subtype (ER/PR 
positive or ER/PR negative) compared to non-users as this was not statistically significant (P = 
0.73).   
Table 4 describes the association between antipsychotic drug use and postmenopausal 
breast cancer diagnosis, stratified by both types of breast cancer as well as types of 
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antipsychotics. This table provides the multivariable adjusted HRs with respective confidence 
intervals at 95% as well as their p-values. Overall, there was no association between 
antipsychotic drug use and breast cancer risk (multivariable-adjusted HR = 1.01, 95% CI = 0.73 
– 1.40). Among participants who used atypical antipsychotics, there was not an increased risk in 
developing invasive  breast cancer (multivariable-adjusted HR = 1.15, 95% CI = 0.37 - 3.56). 
Similarly, typical antipsychotic users were not at an increased risk for in situ breast cancer 
(multivariable-adjusted HR = 2.02, 95% CI = 0.84 - 4.86). 
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CHAPTER V 
DISCUSSION 
 
In this prospective cohort study of postmenopausal women, we observed no association 
between antipsychotic drug use at baseline and breast cancer risk. Null findings were observed 
between atypical antipsychotic drug use and invasive breast cancer as well as between typical 
antipsychotic drug use and in situ breast cancer.  
Several prior epidemiologic studies support a potential relationship between 
antipsychotic drug use and breast cancer risk, but the data are inconsistent. From the six prior 
epidemiologic studies, results varied between null findings and an increased association. Study 
populations within those studies also included both pre- and post-menopausal women. As ours is 
the first study to look solely at postmenopausal women, these results may be able to provide an 
association of the underlying mechanism between antipsychotic drug use and postmenopausal 
breast cancer.  
Our finding of no association between antipsychotic drugs and breast cancer risk is in 
agreement with two prospective cohort studies23,24 and one retrospective cohort study.25 One 
study conducted by Chou et al. found an almost two-fold increase in breast cancer risk with 
antipsychotic drug use (HR = 1.94, 95% CI = 1.43 – 2.63). However, this study utilized a highly 
selective population of schizophrenic patients, who may not be representative of the general 
population. Two separate studies conducted by Pottegard et al. and Wang et al. also reported a 
statistically significant 18% and 16% increase, respectively, in breast cancer risk among 
antipsychotic users. However, these studies included all women over the age of 18. Our results 
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may differ from those studies due to our study population being of older, postmenopausal 
women compared to that of populations inclusive of younger women.  
Our study found a two-fold increased risk of in situ breast cancer among typical 
antipsychotic drug users, although this result was not significant, It is possible that women with 
current antipsychotic prescriptions visit their health care providers more often to get both 
treatment and continuous prescriptions and as such, they may receive referrals for regular 
screening mammography during these clinic visits. Compared to unscreened populations, 
screening mammography is known to lead to an increased diagnosis of in situ breast cancer. 
Therefore, the potential association observed among in situ breast cancer cases may be due to 
screening artifacts rather than an association of true etiology. 
 One limitation of our study is the potential non-differential misclassification of exposure 
assessment. As antipsychotic drug use was measured by having each participant fill a WHI bag 
with current medication, it is possible that participants incorrectly or incompletely filled these 
bags due to stigma surrounding antipsychotics. Also, while the advantage of this is the ability to 
determine actual medication usage of these women. this only accounts for current medications. 
Thus, prior antipsychotic use or recent discontinuation of antipsychotics would have been 
missed, identifying these women as non-users. This is a major limitation as there is potential for 
some women to be past antipsychotic users who will not be represented in this cohort due to the 
nature of the exposure assessment. This will then cause an underestimation of the true risk, 
which would potentially explain our null findings. 
 While our study adjusted for potential confounders such as alcohol consumption, obesity, 
physical activity and diet, these covariates were only collected at baseline. As all these covariates 
are not fixed and can change over time due to varying behaviors and environmental factors, there 
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is potential for residual confounding. This is a major limitation of our study as we were unable to 
incorporate changes to these factors over time due to the nature of its assessment.  
 While the study started off with significant power due to its large sample size, this was 
significantly reduced when we stratified by type of antipsychotic as well as type of breast cancer. 
Due to the major reduction in numbers, power was then compromised and not adequate enough 
to capture significant results, causing an increase in type II error. 
Strengths of our study included its prospective study design as well as extensive data on 
potential confounders. To the best of our knowledge, this is the first study to look at the 
association between typical vs. atypical antipsychotic drug use and risk of developing either in 
situ or invasive breast cancer among postmenopausal women. This study also utilized a relatively 
diverse cohort within the American population, allowing for a large sample size. While the 
majority of our study population was white, there were also women of other races who 
participated, making it less homogenous than prior studies. The WHI study also has over 25 
years of follow-up, providing strong epidemiologic data as well as breast cancer information. We 
expect the biologic and physiologic mechanism to remain the same among all postmenopausal 
women regardless of geographic location or race, making these results potentially generalizable 
to different populations of postmenopausal women. Additionally, many studies had short follow-
up times, which makes it difficult to fully understand the impact of antipsychotics drug on breast 
cancer, as risk for this disease is likely to occur over a period of many years. 
 In summary, our study does not show an overall association between antipsychotic drug 
use and breast cancer risk, though there appears to be suggestive evidence that antipsychotic 
drugs may increase the risk of in situ breast cancer. While this finding was only borderline 
significant, it is important to note how our power was compromised due to small numbers after 
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stratification. To support these findings, additional research should include looking at not just 
breast cancer, but also stratifying it by invasive and in situ breast cancer along with the different 
classes of antipsychotics. This additional data will not only increase the abundance in the 
literature but improve our understanding on whether antipsychotics increase breast cancer risk 
among postmenopausal women. This can then be used for meta-analyses to increase statistical 
power.  
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Table 1: Distribution of baseline characteristics by antipsychotic drug use in the 
Women's Health Initiative (WHI) Study 
  Antipsychotic Drug Use  P-valuea 
  No                 Yes              
Number of participants  119 166 
(99.6) 
478 (0.4)   
Mean age at enrollment (years, SD)  63.1 (7.2) 62.2 (7.2)  <0.0001 
Mean age at menopause (years, SD) 48.1 (6.4) 47.6 (6.8)  <0.0001 
Age group at screening     0.11 
<50 - 59  42 349 (35.5) 182 (38.1)   
60 - 69  53 720 (45.1) 208 (43.5)   
70 - 79+  25 119 (21.1) 88 (18.4)   
BMI     0.007 
Underweight/Normal  42 349 (35.5) 138 (28.9)   
Overweight  41 377 (34.7) 176 (36.8)   
Obese/Extremely obese  35 440 (29.7) 164 (34.4)   
Ethnic group     0.56 
White  99 764 (83.7) 408 (85.4)   
Black/African-American  9944 (8.3) 38 (8.0)   
Other  9458 (7.9) 32 (6.7)   
Education     0.3 
Didn't go to school/Some high 
school/Vocational or training school 
37 619 (31.6) 139 (29.1)   
Some college degree  46 447 (39.0) 184 (38.5)   
Some higher/professional degree  35 100 (29.5) 155 (32.4)   
Family income     <0.0001 
Less than $35 000  47 350 (39.7) 270 (56.5)   
$35 000 to less than $100 000  59 964 (50.3) 180 (37.7)   
$100 000 and more  11 852 (10.0) 28 (5.9)   
Parity     <0.0001 
Nulliparous  13 950 (11.7) 86 (18.0)   
3 or less  69 444 (58.3) 274 (57.3)   
4 and more  35 772 (30.0) 118 (24.7)   
Smoking status     <0.0001 
Never smoker  60 391 (50.7) 211 (44.1)   
Past smoker  50 515 (42.4) 193 (40.4)   
Current smoker  8260 (6.9) 74 (15.5) 
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Table 1 (Continued): Distribution of baseline characteristics by antipsychotic drug 
use in the Women's Health Initiative (WHI) Study 
  Antipsychotic Drug Use  P-valuea 
  No                 Yes              
Alcohol intake     <0.0001 
Never drinker  12 498 (10.5) 49 (10.3)   
Past drinker  21 651 (18.2) 173 (36.2)   
Current drinker  85 017 (71.3) 256 (53.6)   
 
HRT use 
 
     
0.85 
Never user  36 460 (30.6) 143 (29.9)   
Past user  26 659 (22.4) 112 (23.4)   
Current user  56 047 (47.0) 223 (46.7)   
HT arm     0.1 
Not randomized  99 332 (83.4) 417 (87.2)   
E-alone intervention  3530 (3.0) 6 (1.3)   
E-alone control  3602 (3.0) 10 (2.1)   
E + P intervention  6420 (5.4) 21 (4.4)   
E + P control  6282 (5.3) 24 (5.0)   
Female relative had breast cancer     0.48 
No  97 334 (81.7) 397 (83.1)   
Yes  21 832 (18.3) 81 (17.0)   
Abbreviations: SD, standard deviation; BMI, body mass index; HRT, hormone replacement 
therapy; CaD, calcium and vitamin D; DM, dietary modification; HT, hormone therapy 
a P values were calculated using a two-sample t-test for continuous variables and 
chi-square test for categorical variables    
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Table 2: Distribution of baseline characteristics by postmenopausal breast cancer 
diagnosis in the Women's Health Initiative (WHI) Study 
  Postmenopausal Breast Cancer P-valuea 
  No                 Yes              
Number of participants  110 085 
(92.0) 
9559 (8.0)   
Mean age at enrollment (years, SD)  63.1 (7.2) 62.6 (6.9)  <0.0001 
Mean age at menopause (years, SD) 48.0 (6.4) 48.6 (6.1)  <0.0001 
Age group at screening     <0.0001 
<50 - 59  37 135 (33.7) 3374 (35.3)   
60 - 69  49 478 (45.0) 4450 (46.6)   
70 - 79+  23 472 (21.3) 1735 (18.2)   
BMI     0.0008 
Underweight/Normal  39 256 (35.7) 3231 (33.8)   
Overweight  38 181 (34.7) 3372 (35.3)   
Obese/Extremely obese  32 648 (29.7) 2956 (30.9)   
Ethnic group     <0.0001 
White  91 780 (83.4) 8392 (87.8)   
Black/African-American  9363 (8.5) 619 (6.5)   
Other  8942 (8.1) 548 (5.7)   
Education     <0.0001 
Didn't go to school/Some high 
school/Vocational or training school 
35 194 (32.0) 2564 (26.8)   
Some college degree  42 842 (39.0) 3789 (39.6)   
Some higher/professional degree 32 049 (29.1) 3206 (33.5)   
Family income     <0.0001 
Less than $35 000  44 384 (40.3) 3236 (33.9)   
$35 000 to less than $100 000  54 947 (50.0) 5197 (54.4)   
$100 000 and more  10 754 (9.8) 1126 (11.8)   
Parity     <0.0001 
Nulliparous  12 766 (11.6) 1270 (13.3)   
3 or less  63 975 (58.1) 5743 (60.1)   
4 and more  33 344 (30.3) 2546 (26.6)   
Smoking status     <0.0001 
Never smoker  55 196 (50.8) 4686 (49.0)   
Past smoker  46 418 (42.2) 4290 (44.9)   
Current smoker  7751 (7.0) 583 (6.1) 
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Table 2 (Continued): Distribution of baseline characteristics by postmenopausal 
breast cancer diagnosis in the Women's Health Initiative (WHI) Study 
  Postmenopausal Breast Cancer P-valuea 
  No                 Yes              
Alcohol intake     <0.0001 
Never drinker  11 693 (10.6) 854 (8.9)   
Past drinker  20 298 (18.4) 1526 (16.0)   
Current drinker  78 094 (70.9) 7179 (75.1)   
HRT use     <0.0001 
Never user  34 022 (30.9) 2581 (27.0)   
Past user  24 938 (22.7) 1833 (19.2)   
Current user  51 125 (46.4) 5145 (53.8)   
HT arm     <0.0001 
Not randomized  91 588 (83.2) 8161 (85.4)   
E-alone intervention  3339 (3.03) 197 (2.1)   
E-alone control  3360 (3.05) 252 (2.6)   
E + P intervention  5921 (5.4) 520 (5.4)   
E + P control  5877 (5.3) 429 (4.5)   
Female relative had breast cancer    <0.0001 
No  90 464 (82.2) 7267 (76.0)   
Yes  19 621 (17.8) 2292 (24.0)   
Abbreviations: SD, standard deviation; BMI, body mass index; HRT, hormone replacement therapy;  
CaD, calcium and vitamin D; DM, dietary modification; HT, hormone therapy 
a P values were calculated using a two-sample t-test for continuous variables and a chi-square test  
for categorical variables      
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Table 3: Distribution of cancer subtypes by antipsychotic drug use in the 
Women's Health Initiative (WHI) Study 
  Antipsychotic Drug Use  P-valuea 
  No                 Yes              
Breast cancer insitu    0.29 
No  117 373 
(98.5) 
468 (97.9)   
Yes  1793 (1.5) 10 (2.1)   
Breast cancer invasive   0.07 
No  111 293 
(93.4) 
30 (94.9)   
Yes  7873 (6.6) 24 (5.0)   
Subtype     0.71 
ER/PR positive  5777 (84.1) 20 (87.0)   
ER/PR negative  1093 (15.9) 3 (13.0)   
Abbreviations: ER, estrogen receptor; PR, progesterone receptor 
aP values were calculated using a two-sample t-test for continuous variables and a 
 chi-square test for categorical variables     
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Table 4: Estimated hazards ratios for the effects of antipsychotic drug use on breast cancer diagnosis (N = 119 524) 
  All breast cancer 
  Na Age-
Adjusted 
95% CI p-valueb Hazards 
Ratio 
95% CI p-valueb  
Any antipsychotic  9563        
No  9530 1   1    
Yes  33 0.99 0.73, 1.33 0.94 1.01 0.73, 1.40 0.95  
          
Atypical antipsychotic 9563        
No  9561 1   1    
Yes  2 1.2 0.45, 3.19 0.72 0.95 0.31, 2.94 0.93  
          
Typical antipsychotic  9563        
No  9551 1   1    
Yes  12 0.92 0.56, 1.5 0.74 0.89 0.50, 1.57 0.68  
Multivariable Cox model adjusted for age, alcohol intake, BMI, female relative having had breast cancer, education, ethnic group,  
HRT use, HT arm enrollment, parity, smoking status, dietary measures, total energy expended from recreational physical activity  
and age at menopause          
aN refers to cases only        
bP values were calculated using a two-sample t-test for continuous variables and a chi-square test for categorical variables 
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Table 5: Estimated hazards ratios for the effects of antipsychotic drug use on invasive breast cancer diagnosis (N = 119 524) 
   Invasive breast cancer 
   Na Age-
Adjusted 
95% CI p-valueb Hazards 
Ratio 
95 % CI p-valueb  
Any antipsychotic  7899        
No   7875 1   1    
Yes   24 0.84 0.59, 1.20 0.33 0.88 0.60, 1.29 0.5  
           
Atypical antipsychotic  7899        
No   7897 1   1    
Yes   2 1.47 0.55, 3.40 0.44 1.15 0.37, 3.56 0.82  
           
Typical antipsychotic  7899        
No   7891 1   1    
Yes   8 0.69 0.37, 1.29 0.25 0.71 0.35, 1.41 0.33  
Multivariable Cox model adjusted for age, alcohol intake, BMI, female relative having had breast cancer, education, ethnic group, HRT use, HT arm   
enrollment, parity, smoking status, dietary measures, total energy expended from recreational physical activity and age at menopause  
aN refers to cases only          
bP values were calculated using a two-sample t-test for continuous variables and a chi-square test for categorical variables   
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Table 6: Estimated hazards ratios for the effects of antipsychotic drug use on in situ breast cancer diagnosis (N = 119 
524) 
  In situ breast cancer 
  Na Age-
Adjusted 
95% CI p-valueb Hazards 
Ratio 
95% CI p-valueb 
Any 
antipsycho
tic 
 1805       
No  1795 1   1   
Yes  10 1.68 0.99, 2.85 0.05 1.68 0.93, 3.04 0.09 
         
Atypical antipsychotic 1805       
No  1805 1   1   
Yes  0 --c --c 0.91 --c --c 0.91 
         
Typical antipsychotic 1805       
No  1800 1   1   
Yes  5 2.11 1.00, 4.42 0.05 2.02 0.84, 4.86 0.12 
Multivariable Cox model adjusted for age,  alcohol intake, BMI, female relative having had breast cancer, education, ethnic group, HRT use,   
HT arm enrollment, parity, smoking status, dietary measures, total energy expended from recreational physical activity and age at menopause 
aN refers to cases only        
bP values were calculated using a two-sample t-test for continuous variables and a chi-square test for categorical variables  
cNot available due to very small numbers       
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